Lycia Therapeutics
- Biotech or pharma, therapeutic R&D
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade diease-driving circulating and membrane-bound proteins. Our CataLYTAC technology promotes catalytic target degradation for the rapid and sustained clearance of extracellular proteins, offering potential superior efficacy and duration of action compared to traditional inhibitors.
With an initial pipeline focused on autoimmune and inflammatory diseases, our platform is broadly applicable across therapeutic areas.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}